Skip to content

Author

R. Faramand

We have 2 of 225 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

IFN-γ-driven iNOS induction in macrophages mediates CAR T cell resistance in B cell lymphoma

Chimeric antigen receptor (CAR) T cell therapies have revolutionized B cell malignancy treatment, but many patients with large B cell lymphoma (LBCL) experience primary resistance or relapse. To uncover resistance mechanisms, here we examine pre-infusion tumor biopsies and observe that increased immunoregulatory macrop...

SaeBom Lee, A. Pavy, Nolan J. Beatty et al. · 0 citations
Open access Jul 2026

A novel severe toxicity-free, and progression-free survival endpoint predicts outcomes after CD19 chimeric antigen receptor-T cell therapy in large B-cell lymphoma.

TPFS6 remained prognostic for OS and PFS even after accounting for PD/SD, underscoring the impact of severe toxicity on subsequent survival, and may predict long-term outcomes following CAR-T therapy.

A. Saha, Junmin Whiting, R. Mohty et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.